
Patrick Soon-Shiong
$6360.7B
Los Angeles, California, United States
Biography
Medical doctor Patrick Soon-Shiong invented the cancer drug Abraxane. It became a blockbuster thanks to its efficacy against pancreatic cancer.
He sold his drug companies Abraxis in 2010 and American Pharmaceutical Partners in 2008 for a combined $9.1 billion.
He took his cancer drug maker NantKwest public in 2015 and his biotech startup NantHealth public in 2016.
He owns NantWorks, a network of health startups, and has stakes in media firm Tribune Publishing and the Los Angeles Lakers.
He bought the Los Angeles Times and San Diego Tribune for $500 million in June 2018.
In May 2020, Soon-Shiong's ImmunityBio was selected for the federal government's "Operation Warp Speed" to help quickly develop a Covid-19 vaccine.
Financial Assets
Allscripts
NASDAQ: MDRX-USShares: 5,416,000
Benitec Biopharma
NASDAQ: BNTC-USShares: 293,000
Bristol-Myers Squibb Co.
NYSE: BMY-USShares: 13,592,000
Celgene Corporation
NASDAQ: CELG-USShares: 0
Contingent Value Rights for Celgene Corporation
NASDAQ: CELGZ-USShares: 0
Directa Plus
LONDON: DCTA-GBShares: 17,603,000
ImmunityBio Inc
NASDAQ: IBRX-USShares: 307,639,000
ImmunityBio Inc
NASDAQ: IBRX-USShares: 900,000
JAKKS Pacific Inc.
NASDAQ: JAKK-USShares: 0
Liminal BioSciences
TORONTO: LMNL-CAShares: 0
NantHealth
NASDAQ: NH-USShares: 66,803,000
RadNet Inc.
NASDAQ: RDNT-USShares: 891,000
Sorrento Therapeutics
NASDAQ: SRNE-USShares: 0
Tribune Publishing
NASDAQ: TPCO-USShares: 0